I could not be considered to be a trader. I learned the hard way more than 50 years ago I am not good at it. I also don't investigate the financial structure of the companies I invest in for three reasons: (1) except for very tiny and thinly traded ones, I tend to accept the efficient market POV. (Insider knowledge does distort that, but for companies I have shares of, I read the SEC reports of insider sales and tend to get out if they are. A few months ago I got out of ILMN at 44 because of that. I bought it years ago and started a thread about DNA sequencing as there is a lot of jargin I could not understand. CharonZ et. al. helped me.) (2) It is a lot of work to just get the necessary data then decide what it means. (3) The data may not reflect the true financial health of the company - very easy to move debts off the books, etc. While I am lossy at short term timing, I am very good* at telling what will happen a few years from now. So I tend to be a "buy and hold" investor. About half of my portfolio (about 60 stocks now) is in early stage drug developers. Nearly all of the rest is in Brazilian, Indian, Chinese, Australian stocks with a few mineral producers (gold mainly) of Peru and Canada and some other Gold miners which tend to be global. I like early stage drug developers as they have high risk (already factored into the price, so dollar collapse risk is relative small part of total risk) but mainly because I am motivated to hear their presentations via internet to funding conferences, etc. It is truly amazing, and very educational, to follow and deeply understand the dozens of different approaches to major medical problems now being explored. What physics was to the 1900s, cellular processes will be to the 2000s. -------- *I went from a "full needs" scholarship Cornell student who several times could not afford bus fare home for Thanksgiving etc. to current multi-millionare with only a salary as income.